© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#AASLD 2011

Click Here for More Conferences
Click Here for AASLD.org
An Introduction to Hepatitis

BMS Oral Hep C Drug Combo Cures 90% of Null Responders With Genotype 1b in Japanese Study

Combining two experimental oral hepatitis C drugs from Bristol-Myers Squibb (BMS)--daclatasvir, a once-daily NS5a inhibitor, and...

Hep C Protease Inhibitors May Not Be Cost-Effective For Some First-Time Treatment Takers

Hepatitis C virus (HCV) protease inhibitors are not cost-effective for first-time treatment takers with HCV genotype 1 and the IL-28B CC genot...

Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis

People with liver cirrhosis may benefit from daily therapy with a blood thinner to prevent portal vein thrombosis (PVT), a potentially serious...

Interferon-Free Protease/Polymerase Inhibitor Combo Showing Well in Hep C Genotype 1 Study

Boehringer Ingelheim has its eyes set on interferon-free treatment for genotype 1 hepatitis C virus (HCV) infection. The treatment combines tw...

Milk Thistle Extract Comparable to Placebo in Hep C Liver Enzyme Study

Silymarin, an extract of milk thistle (Carduus marianus), had no benefit on levels of the liver enzyme alanine aminotransferase (ALT) in peopl...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Interferon-Free Alisporivir Treatment Showing Promise in Genotype 2/3 Trial

Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclo...

TMC435, Peg-Interferon and Ribavirin Combo Boosts Cure Rates for Hep C Genotype 1

Adding Janssen Therapeutics’ TMC435, a once-daily experimental hepatitis C virus (HCV) protease inhibitor, to pegylated interferon and ribavir...

Testing All Baby Boomers for Hep C Would Find 86% of Infections, Say Researchers

Testing all U.S. baby boomers for hepatitis C virus (HCV) infection would help identify more than 800,000 people living with the virus.

Five-Year Viread Follow-Up: Long-Term Hep B Suppression, Plus Fibrosis and Cirrhosis Improvements

Data continue to mount, indicating that not only can hepatitis B virus (HBV) medications work for many years, but they can also help reverse l...

Hepatitis C Surpasses HIV as Cause of Death in U.S.

Chronic hepatitis C virus (HCV) infection is associated with more deaths than HIV infection, according to sobering new data presented by...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Adding Viread to Baraclude for Hep B Treatment Shows Limited Benefit

There doesn?t appear to be an advantage to combining Baraclude (entecavir) with Viread (Tenofovir) to manage chronic hepatitis B virus (HBV) i...

Gene-Targeting Therapy Shows Promise Against Hepatitis C

Miravirsen, a novel injectable drug targeting a ’microRNA’ known as miR-122 responsible for the accumulation of hepatitis C virus (HCV) in the...

Incivek, Victrelis Working Well in HIV/HCV Coinfection Studies

Roughly 70 percent of people living with HIV and hepatitis C virus (HCV) coinfection have undetectable HCV viral loads after 24 weeks of treat...

PSI-7977, Peg-Interferon, Ribavirin Combo Shines in Genotype 1 Hep C Study

Combining Pharmasset?s once-daily experimental nucleotide analog PSI-7977 with pegylated interferon and ribavirin cured 91 percent of 47 peopl...

Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3

A twelve-week course of Pharmasset?s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...
Advertisement
Treatment News
Newsfeed
Features
Ask Hep